Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib and Thalidomide in Myelofibrosis
NCT03069326Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2017
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of thalidomide in myelofibrosis (MF), sponsored by Memorial Sloan Kettering Cancer Center. Started Feb 2017; status: active, not recruiting.
02
Drugs
thalidomide
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT03069326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03069326.